Coeptis Therapeutics’ Dave Mehalick on Making Cell Therapy Universally Accessible
In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), discussed the company’s innovative approaches in cell therapy, highlighting their focus on making such treatments more universally accessible. Mehalick explained, “What we are working on is not failing, it’s working. We’ve been able to create cells, not have to match those cells at all to the individual patient. Put those same cells in any patient and their body is accepting them and they are going to work.” This strategy represents a shift from the traditional and costly autologous cell therapy to a more cost-effective allogeneic approach, potentially lowering the future cost of cell therapies and making them accessible to a broader population.
Furthermore, Coeptis Therapeutics has been actively forming partnerships with top academic institutions such as Duke University and the University of Pittsburgh. Mehalick shared details about their exclusive license agreement with the University of Pittsburgh, which now includes autoimmune indications for their SNAP-CAR T and SNAP-CAR NK cells. This expansion is significant as it allows the same cellular structures to be used not only against various cancers but also autoimmune diseases like lupus, potentially revolutionizing treatment paradigms across these conditions. He noted, “The beauty of SNAP-CAR is you could use the same cellular structure to attack not only a cancer, any type of cancer at any point on the cancer, but we could use that same cellular structure to attack things like lupus.” This adaptability could lead to more cost-effective treatments and significantly impact patient care in oncology and autoimmune diseases alike.
Create your
podcast in
minutes
It is Free